LGM
IOVA icon

Logos Global Management’s Iovance Biotherapeutics IOVA Stock Holding History

Logos Global Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,000,000
Closed -$8.13M – 63
2023
Q4 		$8.13M Hold
1,000,000
– – 0.76% 29
2023
Q3 		$4.55M Buy
+1,000,000
New +$6.53M 0.61% 40

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Logos Global Management's IOVA Position: Q2 2022 in Review

Logos Global Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2022, closing a stake of 1,000,000 shares — an estimated $16.6M sold.

Logos Global Management first reported a position in IOVA in Q4 2019 and held it in 5 quarters. The position peaked at $29.3M in Q2 2021. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

  • Logos Global Management reported no remaining Iovance Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Logos Global Management sold 1,000,000 Iovance Biotherapeutics shares in Q2 2022, an estimated $16.6M.
  • Logos Global Management first reported a position in Iovance Biotherapeutics in Q4 2019 and held it in 5 quarters.
  • Logos Global Management's Iovance Biotherapeutics position peaked at $29.3M in Q2 2021.
  • 237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on Logos Global Management's 13F filing for Q2 2022, filed 15 Aug 2022.